FARMINGDALE, N.Y.--(BUSINESS WIRE)--March 14, 2006--Enzo Biochem, Inc. (NYSE:ENZ) announced today that its wholly owned subsidiary Enzo Therapeutics has initiated a Phase II clinical trial to evaluate its immunomodulatory candidate drug EGS21 as a therapeutic for managing Crohn’s disease. A Phase I safety trial of EGS21 was successfully concluded last year. The study is being conducted at Hebrew University Hadassah Medical Center where subject enrollment is proceeding.
